Bayer Ag · XETR:BAYN

Bayer — 25th European Society of Retina Specialists (EURETINA) Congress 2025

10 slides from Bayer's conference presentation, Sep 4, 2025

  1. Slide 1: Early Insights From Real-World Use of Aflibercept 8 mg Among Eyes With DME Switching From Other Anti-VEGF Agents

    Early Insights From Real-World Use of Aflibercept 8 mg Among Eyes With Diabetic Macular Edema Switching From Other Anti-VEGF Agents Edoardo Midena, MD, PhD,1 Michael Javaheri, MD,2 Steven Sherman, MPH,3 Keran Moll, PhD,3 Dana Murdock, PhD,3 Nick Boucher, BS,4 Rishi P. Singh, MD,5 Ferhina S. Ali, MD,

  2. Slide 2: Disclosures

    Disclosures • Edoardo Midena: No conflicts • MJ: Acted as a speaker and consultant and partaken in advisory boards with Genentech and Regeneron Pharmaceuticals, Inc. SS, KM, AND DM : Employees and stockholders of Regeneron Pharmaceuticals, Inc. NB: Employee of Vestrum Health. RPS: Personal fees from

  3. Slide 3: Inclusion Criteria and Attrition

    Inclusion Criteria and Attrition Number of eyes Inclusion criteria IRIS Vestrum Eyes with ≥1 diagnosis of DME at the index datea receiving aflibercept 8 mg and 30,266 7845 no other anti-VEGF agent or other treatmentsb Adult patients (aged ≥18 years) with no diagnosis of nAMD or RVO during the 12 mon

  4. Slide 4: Outcomes

    Outcomes • Injection intervals were evaluated for eyes that were consistently treated with anti-VEGF (defined as ≥6 months of treatment with an average injection interval of ≤8 weeks for the most recent anti-VEGF agent) and ≥1 post-initial dosing phase injection • The last observed injection interva

  5. Slide 5: Patient Characteristics at the Index Date

    Patient Characteristics at the Index Date IRIS Vestrum (n=10,092) (n=3706) Age, mean (SD), years 66.5 (10.5) 66.3 (10.9) Males, n (%) 5576 (55) 2033 (55) Race/ethnicity, n (%) Hispanic or Latino 866 (10) NA White 5548 (62) NA Black or African American 1025 (12) NA Asian or Pacific Islander 276 (3) N

  6. Slide 6: Treatment Patterns During Follow-Up

    Treatment Patterns During Follow-Up IRIS Vestrum (n=10,092) (n=3706) Duration of post-switch follow-up, days Mean (SD) 167 (109) 246 (110) Median (Q1, Q3) 162 (71, 245) 252 (175, 329) Number of aflibercept 8-mg injections during follow-upa Mean (SD) 3 (2) 3 (1) Median (Q1, Q3) 3 (1, 4) 3 (2, 4) aInc

  7. Slide 7: Anti-VEGF Agent Used Before Switching to Aflibercept 8 mg

    Anti-VEGF Agent Used Before Switching to Aflibercept 8 mg IRIS (n=10,092) Vestrum (n=3706) Ranibizumab Ranibizumab Bevacizumab 2.6%a Brolucizumab Bevacizumab 2.4%b 9.4% 0.1% 7.4% Faricimab Faricimab 8.2% 13.1% Aflibercept 2 mg Aflibercept 2 mg 74.8% 82.1% Data represent the proportion of eyes receiv

  8. Slide 8: Injection Interval Extension of ~3-4 Weeks After Switching to Aflibercept 8 mg

    Injection Interval Extension of ~3-4 Weeks After Switching to Aflibercept 8 mg in Eyes With an Average Pre-Switch Injection Interval of 4 to <6 Weeksa IRIS (n=959) Vestrum (n=224) 120 Mean change (SD): +23 (25) days 120 Mean change (SD): +26 (19) days Median (Q1, Q3): +21 (12, 28) Median (Q1, Q3): +

  9. Slide 9: Injection Interval Extension of ~2-3 Weeks After Switching to Aflibercept 8 mg

    Injection Interval Extension of ~2-3 Weeks After Switching to Aflibercept 8 mg in Eyes With an Average Pre-Switch Injection Interval of ≥6 to 8 Weeksa IRIS (n=1321) Vestrum (n=429) 120 Mean change (SD): +16 (25) days 120 Mean change (SD): +19 (27) days Median (Q1, Q3): 14 (1, 26) Median (Q1, Q3): 14

  10. Slide 10: Conclusions

    Conclusions • Most eyes were consistently treated with aflibercept 2 mg prior to initiating aflibercept 8-mg treatment • Eyes switching to aflibercept 8 mg after consistent treatment with a previous anti-VEGF agent had an average injection interval extension of: – Approximately 3-4 weeks for eyes wi

Bayer — 25th European Society of Retina Specialists (EURETINA) Congress 2025 on 6ix